Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Multiplexed activation of endogenous genes by CRISPRa elicits potent anti-tumor immunity

PROVIDER: PRJNA553203 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9652957_1.fastq.gz	Fastqsanger.gz
	SRR9652957_2.fastq.gz	Fastqsanger.gz
	SRR9652958_1.fastq.gz	Fastqsanger.gz
	SRR9652958_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Multiplexed activation of endogenous genes by CRISPRa elicits potent anti-tumor immunity

Project description:Multiplexed activation of endogenous genes by CRISPRa elicits potent anti-tumor immunity

| PRJNA553242 | ENA

Multiplexed activation of endogenous genes by CRISPRa elicits potent anti-tumor immunity

Project description:Immunotherapy has transformed cancer treatment. However, current immunotherapy modalities face many limitations. Here, we developed a new form of immunotherapy that elicits anti-tumor immunity through multiplexed activation of endogenous genes. We leveraged the CRISPR activation (CRISPRa) system to directly augment the in situ expression of endogenous genes, and thereby the presentation of tumor antigens, leading to dramatic anti-tumor immune responses. Deploying this as a cell-based vaccination strategy showed efficacy in both prophylactic and therapeutic settings. Intratumoral adeno-associated virus delivery of CRISPRa libraries elicited strong anti-tumor immunity across multiple cancer types. Precision targeting of mutated gene sets eradicated a large fraction of established tumors at both local and distant sites. This treatment modality led to alterations of the tumor microenvironment, marked by enhanced T cell infiltration and anti-tumor immune signatures. Multiplexed endogenous gene activation may serve as a versatile and highly scalable strategy to elicit potent immune responses against cancer.

2020-04-14 | GSE133983 | GEO

Anti-CD4 treatment affects TCR repertoire of CD8+ T cells

Project description:Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes and promoting CD8+ T cell reactivity against tumor cell-derived antigens. We conducted TCR repertoire analysis of anti-CD4-exposed endogenous CD8+ T cells to investigate the expansion pattern of the cell population.

2021-08-03 | GSE181280 | GEO

LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade

Project description:Chromatin regulators play a broad role in regulating gene expression, and when gone awry, can lead to cancer. Here we demonstrate that ablation of the histone demethylase LSD1 in cancer cells increases repetitive element expression, including ERVs, and decreases expression of RNA-induced silencing complex (RISC) components. Significantly, this leads to dsRNA stress and activation of type 1 interferon, which stimulates anti-tumor T cell immunity and restrains tumor growth. Furthermore, LSD1 depletion enhances tumor immunogenicity and T cell infiltration in poorly immunogenic tumors, and elicits significant responses of checkpoint blockade-refractory mouse melanoma to anti-PD-1 therapy. Consistently, TCGA data analysis shows an inverse correlation between LSD1 expression and CD8+ T cell infiltration in various human cancers. Our study identifies LSD1 as a potent inhibitor of anti-tumor immunity and responsiveness to immunotherapy, and suggests LSD1 inhibition combined with PD-(L)1 blockade as a novel cancer treatment strategy.

2018-06-21 | GSE112230 | GEO

Project description:Commensal microbe elicits iron sequestration in tumor macrophages enhancing anti-tumor immunity

| PRJNA991251 | ENA

TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice

Project description:TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice

| PRJNA862720 | ENA

Gene expression data of CD8+ T cells from C57BL/6 mouse

Project description:Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes and promoting CD8+ T cell reactivity against tumor cell-derived antigens. We used microarrays to investigate anti-CD4-induced gene-expression change of CD8+ T cells.

2021-07-18 | GSE180291 | GEO

Anti-CD4 treatment increases tumor-suppressive IL18Rαhi CD8+ T cells

Project description:Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes and promoting CD8+ T cell reactivity against tumor cell-derived antigens. We conducted single-cell transcriptome analysis of anti-CD4-exposed lymphoid cells to investigate the detailed mechanism.

2021-07-30 | GSE180991 | GEO

Mus musculus

Project description:Transient activation of tumor-associated macrophages boosts anti-tumor immunity

| PRJNA389686 | ENA

MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in nematodes, mice and human cells

Project description:CRISPR-mediated gene activation (CRISPRa) is a promising therapeutic gene editing strategy without inducing DNA double-strand breaks (DSBs). However, in vivo implementation of these CRISPRa systems remains a challenge. Here, we report a compact and robust miniCas9 activator (termed miniCAFE) for in vivo activation of endogenous target genes. The system relies on recruitment of an engineered minimal nuclease-null Cas9 from Campylobacter jejuni and potent transcriptional activators to a target locus by a single guide RNA. It enables robust gene activation in human cells even with a single DNA copy and is able to promote lifespan of C. elegans through activation of longevity-regulating genes. As proof-of-concept, delivered within an all-in-one adeno-associated virus (AAV), miniCAFE can activate Fgf21 expression in the liver and regulate energy metabolism in adult mice. Thus, miniCAFE holds great therapeutic potential against human diseases.

2021-04-21 | GSE164452 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data